Camptothecin liposomal - Aphios

Drug Profile

Camptothecin liposomal - Aphios

Alternative Names: Camposomes; Liposome encapsulated camptothecin

Latest Information Update: 24 Dec 2014

Price : $50

At a glance

  • Originator Aphios Corporation
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 24 Dec 2014 Camptothecin liposomal - Aphios is available for licensing as of 24 Dec 2014.
  • 18 Nov 2014 Aphios has patent protection for nanotechnology co-encapsulation of combination drugs & drug products in USA
  • 22 Jun 2009 Camptothecin liposomal is still in preclinical trials for Colorectal cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top